Johannesburg – The South African Health Products Regulatory Authority (SAHPRA) has recalled specific batches of Citro-Soda Regular following a potential contamination risk identified at the Adcock Ingram Clayville manufacturing facility in Johannesburg.
SAHPRA said the recall was limited to the affected batches of Citro Soda Regular produced at the Adcock Ingram Clayville facility, as outlined in the recall listing below:
- Citro-Soda Regular 60 g
- Citro-Soda Regular 120 g
- Citro-Soda Regular 4 g x 30 Sachets
At a media briefing on Tuesday, 24 March 2026, SAHPRA said during inspections, the regulator found:
- Metal fragments and black residue on production equipment
- Damaged, rusted machinery and pieces of broken conveyor belts
- Inadequate powder control and dust removal systems, allowing particles to spread
- Lack of proper cleaning procedures and accumulated residue in machines
- No suitable systems to prevent contamination
SAHPRA said these issues raised concerns that foreign material could have entered the product, posing a health risk to consumers.
The recall was limited to affected batches (mainly those with batch numbers starting with “C” and expiry dates on or before November 2027).
SAHPRA said other Citro-Soda variants (such as Cranberry) and products made at different facilities are not affected.
Consumers are advised to check batch details and return affected products for a refund.
During the briefing, SAHPRA explained that the inspection and recall were part of its routine regulatory oversight and risk-based approach to safeguarding public health.
SAHPRA also reassured the public that it continues to actively monitor the situation and engage with the manufacturer to ensure full compliance with regulatory requirements.
Retail pharmacies, wholesalers, and distribution centres have been instructed to cease the sale of affected batches and to return all stock to their respective suppliers.
SAHPRA advised consumers who have purchased the affected products to return them to the nearest health facility, pharmacy, or store.
“The safety and well-being of the public remain our highest priority. SAHPRA will continue to act decisively and transparently to ensure that all health products on the market meet the required standards of quality, safety, and efficacy,” said Dr. Boitumelo Semete-Makokotlelathe, Chief Executive Officer of SAHPRA.
Anyone who may have consumed the affected products and is experiencing any adverse side effects is urged to visit their nearest health facility and also report such incidents to SAHPRA.
